Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lifeward Ltd. - Ordinary Shares (NQ:LFWD)

0.5421 -0.0049 (-0.90%)
Streaming Delayed Price Updated: 11:09 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lifeward Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Appoints Bob Marshall as Chairman of the Board
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
From Lifeward Ltd.
Via GlobeNewswire
News headline image
UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury. 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Ltd. Reports Third Quarter 2025 Financial Results
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Report Third Quarter Financial Results on November 14, 2025
From Lifeward Ltd.
Via GlobeNewswire
News headline image
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Ltd. Reports Second Quarter 2025 Financial Results
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Report Second Quarter Financial Results on August 14, 2025
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region
Expansion adds additional AlterG dealer coverage to 6 countries throughout the Gulf Cooperation Council region 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Announces Closing of $2.6 Million Public Offering
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Announces Pricing of $2.6 Million Public Offering
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Administrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary
Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments. 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Names Mark Grant as New CEO
Industry veteran brings 30 years of commercial leadership experience 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Present at Sidoti Virtual Investor Conference on May 21
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Ltd. Reports First Quarter 2025 Financial Results
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons
Three-year program examined opportunities to integrate artificial intelligence technology into future generations of ReWalk Exoskeletons 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025
From Lifeward Ltd.
Via GlobeNewswire
News headline image
First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton
Cooperation between Lifeward and Beilinson Hospital marks the first step towards a national policy in Israel on Exoskeleton training and procurement 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market
From Lifeward Ltd.
Via GlobeNewswire
News headline image
FDA Issues Clearance for ReWalk 7 Exoskeleton
Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward and CorLife Finalize Partnership to Expand Workers’ Compensation Access to ReWalk Exoskeleton
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use
New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Announces CEO Transition
From Lifeward Ltd.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.